Advances in Technologies to Improve Ventricular Ablation Safety and Efficacy

AbstractPurpose of ReviewThis review focuses on advances within the field of cardiac electrophysiology that have helped to improve the safety and efficacy of ventricular arrhythmia ablation.Recent FindingsImprovements in three-dimensional electroanatomic mapping systems and catheters allow providers to generate high-resolution maps in less time while identifying critical areas of arrhythmogenic substrate with greater efficiency and possibly better accuracy. Advanced imaging integration into the mapping systems have improved pre- and periprocedural planning and safety. Novel ablation catheters and techniques have improved the ability to target and deliver effective lesions to areas that are critical in sustaining ventricular arrhythmias. Risk prediction algorithms have been developed to improve the ability to determine those undergoing VA ablation that are at highest risk for acute hemodynamic decompensation, and for whom hemodynamic mechanical support should be instituted, allowing for this therapy to be able to be more safely performed in even those with advanced heart failure. Finally, emerging techniques undergoing development may further improve the safety and efficacy of ventricular arrhythmia management.SummaryRecent advancements in the field of cardiac electrophysiology now enable us to approach ablation of ventricular arrhythmias with increasing precision, safety, and success. With the increasing tools available to the electrophysiologist, ventricular arrhythmia ablat...
Source: Current Cardiovascular Risk Reports - Category: Cardiology Source Type: research

Related Links:

ConclusionsLeft bundle branch block-induced cardiomyopathy emerges as a distinct pathological entity, promptly identifiable in a minority but not negligible proportion of patients with newly diagnosed DCM and LBBB, using a series of diagnostic criteria including CMR and genetic testing. Further studies are needed to better elucidate the clinical course of LBBB-ICMP.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Short Communication Source Type: research
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate canc...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Continuous flow left ventricular assist devices (CF-LVAD) have become important therapy for patients with advanced heart failure. Post CF-LVAD ventricular arrhythmia (VA) has emerged as a notable determinant of recipients ’ morbidity and mortality. Smaller, single institutional series have assessed pre-implant factors predictive of post CF-LVAD VA and its impact on patient outcomes. However, no large-scale studies of CF-LVAD recipients have been reported using the INTERMACS registry to date.
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research
Impact of heart failure (HF) medications on ventricular arrhythmia (VA) is must less robust than its impact on HF hospitalizations and survival.
Source: Heart Rhythm - Category: Cardiology Authors: Source Type: research
Recent evidence suggests that an implantable cardioverter defibrillator (ICD) in non-ischemic cardiomyopathy (NICM) may not offer mortality benefit. We aimed to investigate if etiology of heart failure and strain echocardiography can improve risk stratification of life threatening ventricular arrhythmia (VA) in heart failure patients.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Rev Cardiovasc Med. 2021 Jun 30;22(2):415-428. doi: 10.31083/j.rcm2202047.ABSTRACTHeart failure (HF) is a complex clinical syndrome characterised by significant morbidity and mortality worldwide. Evidence-based therapies for the management of HF include several well-established neurohormonal antagonists and antiarrhythmic drug therapy to mitigate the onset of cardiac arrhythmia. However, the degree of rate and rhythm control achieved is often suboptimal and mortality rates continue to remain high. Implantable cardioverter-defibrillators (ICDs), cardiac resynchronization (CRT), and combined (CRT-D) therapies have emerged as...
Source: Reviews in Cardiovascular Medicine - Category: Cardiology Authors: Source Type: research
More News: Arrhythmia | Cardiology | Cardiovascular | Heart | Heart Failure | Ventricular Arrhythmia